Browse > Article
http://dx.doi.org/10.5012/jkcs.2012.56.2.236

Design and Synthesis of p-hydroxybenzohydrazide Derivatives for their Antimycobacterial Activity  

Bhole, Ritesh.P. (Department of Pharmaceutical Chemistry, CEPERT, Pad. Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research)
Borkar, Deepak.D. (Department of Pharmaceutical Chemistry, Sharad Pawar College of Pharmacy)
Bhusari, Kishore.P. (Department of Pharmaceutical Chemistry, Sharad Pawar College of Pharmacy)
Patil, Prashant.A. (Department of Pharmaceutical Chemistry, Sharad Pawar College of Pharmacy)
Publication Information
Journal of the Korean Chemical Society / v.56, no.2, 2012 , pp. 236-245 More about this Journal
Abstract
The main mycobacterial infection in human is tuberculosis caused by Mycobacterium tuberculosis. Tuberculosis is the leading infectious cause of death in the world. Therefore there is continuing and compelling need for new and improved treatment for tuberculosis. The entire logic towards design of new compounds containing 4-hydroxy-N'-(1,3-thiazoldin- 2-yldene)benzohydrazide moiety is basically for superior antimycobacterial activity. The recent advances in QSAR and computer science have provided a systematic approach to design a structure of any compound and further, the biological activity of the compound can be predicted before synthesis. The 3D-QSAR studies for the set of 4-hydroxy-N'-(1,3-thiazoldin- 2-yldene)benzohydrazide and their derivatives were carried out by using V-life MDS (3.50). The various statistical methods such as Multiple Linear Regression (MLR), Partial Least Square Regression (PLSR), Principle Component Regression(PCR) and K nearest neighbour (kNN) were used. The kNN showed good results having cross validated $r^2$ 0.9319, $r^2$ for external test set 0.8561 and standard error of estimate 0.2195. The docking studies were carried out by using Schrodinger GLIDE module which resulted in good docking score in comparison with the standard isoniazid. The designed compounds were further subjected for synthesis and biological evaluation. Antitubercular evaluation of these compounds showed that (4.a), (4.d) and (4.g) found as potent inhibitor of H37RV.
Keywords
3D QSAR; GLIDE; Benzohydrazide;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Kolossvary, I.; Guida, W. C. J. Am. Chem. Soc. 1996, 118, 5011.   DOI   ScienceOn
2 SMARTS-Language for Describing Molecular Patterns, Daylight Chemical Information Systems, Inc., Aliso Viejo, CA.
3 Maccari, R.; Ottana, R.; Vigorita, M. G. Bioorg. Med. Chem. 2005, 15, 2509.   DOI   ScienceOn
4 Zhong, X.; Wei. L. H.; Liu, W. S.; Wang, D. Q.; Wang, X. Bioorg. Med. Chem. 2007, 17, 3774.   DOI   ScienceOn
5 Osyanin, V. A.; Purygin, P. P.; Belovsova, Z. P. Rus. J. Gen. Chem. 2005, 75, 111.   DOI   ScienceOn
6 Patole, J.; Sandbhor, U.; Padhye, S.; Deobagkar, D. N.; Anson, C. E.; Powell, A. Bioorg. Med. Chem. 2003, 13, 51.   DOI   ScienceOn
7 Koschucharov, R.; Ivanov, G. Pharmazie 1960, 15, 492.
8 Paigeen, K. Prog. Nucleic. Acid. Res. Mol. Biol. 1989, 37, 155.   DOI
9 Ho, J.; Hsu, S. C.; Chen, J. S. Eur. J. Clin. Invest. 1986, 16, 361.   DOI   ScienceOn
10 Inanov, N. Chem. Abst. 1959, 53, 15038.
11 Mazouz, F.; Gueddari, S.; Burstein, C.; Mansy, D.; Milcent, R. J. Med. Chem. 1993, 36, 1157.   DOI   ScienceOn
12 Tan, Y. T.; Tillett, D. J.; Mckay, I. A. Mol. Med. Today. 2000, 6, 309.   DOI   ScienceOn
13 Ernest, Carron MC. U.S. Patent 3290213.
14 Davidson, P. T.; Le, H. Q. Drugs 1993, 43, 651.
15 Vincent, T. A. Int. J. Antimicrob. Agents. 2000, 16, 317.   DOI   ScienceOn
16 PHASE 2.0, Schrodinger, LLC, New York, 2006.
17 Ligprep 2.0, Schrodinger, LLC, New York, 2006.
18 Ke, Y. S.; Quin, X. Y.; Wang, N.; Yang, Q. Eur. J. Med. Chem. 2008, 43, 1.   DOI   ScienceOn
19 MacroModel 9.1, Schrodinger, LLC, New York, 2006.
20 Halgren, T. A. J. Comput. Chem. 1996, 17, 520.   DOI
21 MacroModel 2.0, User Manual, Schrodinger, LLC, New York, 2006.
22 Chang, G.; Guida, W.; Still, W. C. J. Am. Chem. Soc. 1989, 111, 4379.   DOI
23 Delgado, J. N.; Remers, W. A. Wilson and Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry, 11th ed.; Lippincott-Raven: Philadelphia, 2002, pp 1-3.
24 Peter, G.; Maggiora, Synder, J. P.; Cohen, C. N. Guide Book on Molecular Modeling In Drug Design, 1st ed.; Academic Press: 1966, pp 216-32.
25 Gerhard, K.; Abrahum, U. J. Computer Aided Molecular Designs, 1st ed.; Harward Press: London, 1999, pp 473-98.
26 http://www.netsci.org/science/compchem/drugdesign2.htm.
27 Claude, C. N. Guidebook on Molecular Modeling In Drug Design, 1st ed.; Elsevier: 2009, pp 94-100.
28 Carter, R. C.; Grassy, G.; Kubinyl, H.; Martin, Y. C.; Willett, P. Annual Reports in Medicinal Chemistry 1998, 33, 397.   DOI
29 Propst, C. L.; Perun, T. J. Computer Aided Drug Design Methods and Application; Marcel Dekker: New york, 1989; Vol. 4, p 12.
30 Kulkarni, V. M.; Bothara, K. G. Textbook of Drug Design, 2nd ed.; Nirali Prakashan: 2003; pp 189-211.
31 Richet, M. C. Compt. Rend. Soc. Biol. 1893, 45, 885.
32 Overton, E.; Lipnick, R. L. Studies on Narcosis; Chapman and Hall: London, 1991.
33 Rao, R. P. J. Indian. Chem. Soc. 1961, 38, 784.
34 Wilson, F. J.; Burns, R. J. Chem. Soc. 1922, 121, 870.   DOI
35 Bhole, R. P.; Bhusari, K. P. QSAR Comb. Sci. 2009, 28, 405.
36 Joshi, S. D.; Vagdevi, H. M.; Vaidya, V. P. Eur. J. Med. Chem. 2008, 43, 1989.   DOI   ScienceOn
37 Rollas, S.; Kiraz, M. Eur. J. Med. Chem. 1999, 34, 1093.   DOI   ScienceOn
38 Vijaya Raj K. K.; Narayana, B.; Ashalatha, B.; Sarojani, B. K. Eur. J. Med. Chem. 2007, 42, 425.   DOI   ScienceOn